Merck Sharp + Dohme Corp.

Merck + Co., Inc.

F. Hoffmann-la Roche Ag

Genentech, Inc.

Merck Frosst Canada & Co.

Merck & Dohme Limited

Alan John Nadin

Timothy Harrison

Andrew Pate Owens

Martin Richard Teall

Duncan Edward Shaw

Ian Churcher

Brian John Williams

Kevin Dinnell

Paul Joseph Oakley

Sonia Kerrad

Jose Luis Castro Pineiro

Timothy Jason Sparey

Susannah Williams

Stephen Colin Price

Ian James Collins

Christopher Richard Moyes

Timothy Colin Hancox

Neil Anthony Pegg

Andrew Madin

Michael Rowley

Stephen Robert Fletcher

Paul David Leeson

Graeme Irvine Stevenson

Toby Jonathan Blench

Joseph George Neduvelil

Mandy Christine Beswick

Elsa Amandine Dechaux

Susannah William

Janusz Jozef Kulagowski

Bruce D Dorsey

Richard Thomas Lewis

Patrice C Belanger

Jules A Shafer

Adrian Leonard Smith

Stephen John Lewis

Yueming Li

Alexander Richard Guiblin

Peter Alan Hunt

Richard Alexander Jelley

Ming-Tain Lai

Joanne Claire Hannam

Joanne Thomson

Dennis C Dean

Mark Steven Shearman

Mohinder Sardana

Edward Giles McIver

Stephen J Gardell

Karl Richard Gibson

Jahusz Jozef Kulagowski

Sonia Kerrard

Janusz Josef Kulagowski

Paul Goldsmith

Alan Hudson

Thienopyrimidines of formula (I) wherein W and Rto Rare as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110&#x3b4; isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. 

Thienopyrimidine derivatives as P13K inhibitors

Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. 

Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; Rand Rform, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; Ris H or C-Calkyl; and Ris an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110&#x3b4; isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders. 

Compounds of formula I: inhibit the processing of APP by gamma-secretase and hence find use in treatment of Alzheimer's disease.

Gamma-secretase inhibitors

Novel sulphones of Formula I are disclosed: wherein A completes a 4-7 membered ring optionally comprising up to two heteroatoms. The compounds modulate the action of &#x3b3;-secretase and are therefore useful in the treatment or prevention of Alzheimer's disease.

Sulphones which modulate the action of gamma-secretase

Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease.

Sulphones which modulate the action of gamma secretase

Compounds of formula I: inhibit gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.

Cyclohexyl sulphones as gamma-secretase inhibitors

A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.

Sulphonamido-substituted bridged bicycloalkyl derivatives

Compounds of formula I: inhibit the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

Cyclic sulfonamides for inhibition of gamma-secretase

Novel sulphones of formula I are disclosed:  The compounds modulate the processing of amyloid precursor protein by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

Cyclohexyl sulphones

A novel class of 1,4- and 1,5-benzodiazepines of formula (I) is disclosed. The compounds modulate the processing of amyloid precursor protein by &#x3b3;-secretase, and hence find use in the treatment or prevention of conditions associated with the deposition of &#x3b2;-amyloid, such as Alzheimer's disease 

Benzodiazepine derivatives as APP modulators

Compounds of formula (I) are disclosed. The compounds inhibit the action of gamma secretase, and hence find use in the treatment and prevention of Alzheimer's disease.

Benzodiazepine derivatives as inhibitors of gamma secretase

Novel sulphones of formula I are disclosed: The compounds modulate the processing of amyloid precursor protein by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

A class of compounds is disclosed which are diasteroisomers of a known class of protease inhibitors. The compound inhibit gamma-secretase, and find use in the treatment of and/or prevention of Alzheimer's disease.

Compounds of formula I:inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.

Growing community of inventors

Sawbridgeworth, United Kingdom

Alan John Nadin